(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.02%) $0.926
(-0.06%) $10.83
(-0.11%) $0.791
(-0.24%) $92.35
Live Chart Being Loaded With Signals
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada...
Stats | |
---|---|
Today's Volume | 26 576.00 |
Average Volume | 99 141.00 |
Market Cap | 4.24M |
EPS | $0 ( 2024-02-11 ) |
Next earnings date | ( $-0.0100 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.880 |
ATR14 | $0 (0.00%) |
APPILI THERAPEUTICS INC Correlation
10 Most Positive Correlations | |
---|---|
ISV.TO | 0.832 |
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
APPILI THERAPEUTICS INC Financials
Annual | 2022 |
Revenue: | $334 177 |
Gross Profit: | $327 911 (98.12 %) |
EPS: | $-0.0813 |
Q3 | 2023 |
Revenue: | $478 397 |
Gross Profit: | $475 004 (99.29 %) |
EPS: | $-0.00130 |
Q2 | 2023 |
Revenue: | $337 313 |
Gross Profit: | $333 871 (98.98 %) |
EPS: | $-0.00810 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $-3 442.00 (0.00 %) |
EPS: | $-0.0128 |
Financial Reports:
No articles found.
APPILI THERAPEUTICS INC
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators